NCT07331753 The Outcomes of Fat Grafting Combined With Latissimus Dorsi Muscle Flap for Delayed Breast Reconstruction After Mastectomy
| NCT ID | NCT07331753 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sohag University |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-11-01 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The outcomes of fat grafting combined with latissimus dorsi muscle flap for delayed breast reconstruction after mastectomy
Eligibility Criteria
Inclusion Criteria: * female patient indicated for skin sparying mastectomy Exclusion Criteria: * female patients with stage 4 breast cancer
Frequently Asked Questions
Who can join the NCT07331753 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07331753 currently recruiting?
Yes, NCT07331753 is actively recruiting participants. Visit ClinicalTrials.gov or contact Sohag University to inquire about joining.
Where is the NCT07331753 trial being conducted?
This trial is being conducted at Sohag, Egypt.
Who is sponsoring the NCT07331753 clinical trial?
NCT07331753 is sponsored by Sohag University. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.